SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, Parkinson’s disease, spinal cord injury, and Alzheimer’s disease; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.
तुलना करने के लिए मीट्रिक्स | 4592 | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंध4592पीअर्सक्षेत्र | |
---|---|---|---|---|
पी/ई अनुपात | −19.7x | −5.0x | −0.6x | |
PEG अनुपात | −0.38 | −0.10 | 0.00 | |
क़ीमत/बुक | 93.0x | 4.0x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 54.1x | 3.1x | |
अपसाइड (विश्लेषक लक्ष्य) | 23.6% | 69.1% | 48.8% | |
उचित मूल्य अपसाइड | अनलॉक करें | 9.4% | 7.5% | अनलॉक करें |